

5

10

UNITED STATES PATENT APPLICATION

LINKER ARMS FOR NANOCRYSTALS
AND COMPOUNDS THEREOF

15

Be it known that we Sandra J. Rosenthal, Ian D. Tomlinson, and
Tadd Kippeny, all of Nashville, Tennessee have invented new and useful
linker arms for nanocrystals and compounds thereof.

20

Field of the Invention

This invention generally relates to nanocrystals, linker arms for
nanocrystals, and compounds resulting therefrom. Furthermore, this
invention relates to labeling techniques using the compounds of the
present invention.

25

Background of the invention

Semi-conducting nanocrystals, also referred to as quantum dots,
5 have many advantages over traditional dye molecules in the areas of
fluorescent labeling. Fluorescent nanocrystal labeling has broad
application in the biomedical sciences. For example, the labeling
technique of the present invention provides improved and widely
applicable methods for detecting biomolecules and for scrutinizing
10 biomolecular processes.

Currently quantum dots are being used as fluorescent tags capable
of tracing specific substances within cells. Quantum dots can be
activated to glow with different colors, so it is easier to use quantum dots
in tandem than combinations of conventional fluorescent dyes. See
15 "Semiconductor Beacons Light up Cell Structures" Service, Science, Vol.
281. The conventional fluorescent dye, typically made from small organic
dye molecules can be toxic, can quench quickly, and can be difficult to
use in tandem, since typically each dye must be excited with photons at
a different wavelength. Additionally, compared with conventional coloring
20 agents such as rhodamine 6G or other organic dyes, the quantum dots
produce narrower and much brighter fluorescence spectra. See
"Quantum Dots Meet Biomolecules", Jacoby. With the quantum dots, or

nanocrystals, the absorbency onset and emission maxima shift to a higher energy with decreasing size. The excitation typically tracks the absorbency, resulting in a tunable fluorophore that can be excited efficiently at any wavelength shorter than the emission peak, yet will emit

5 with the same characteristic a narrow, symmetric spectrum regardless of the excitation wavelength. See "Semiconductor Nanocrystals as Fluorescent Biological Labels", Bruchez, et al., Science, Vol. 281, 1998. The absorbance onset and emission maximum shift to higher energy as the size of the nanocrystal decreases. Because the excitation tracks

10 absorbance, the nanocrystals can be excited at many wavelengths, yet still they emit the same narrow, symmetric peak. By varying the material used or the size of the quantum dot, the color can be changed. Additionally, a range of quantum dots of different colors may be excited with a single wavelength and detected simultaneously. See "Bright Lights

15 for Biomolecules", Analytical Chemistry News and Features, December 1998. Thus, the quantum dots, or semiconducting nanocrystals, are much more flexible and advantageous when used in assays.

The attachment of biologically active ligands to nanocrystals including, for example, cadmium selenide nanocrystals, is a new method

20 of producing novel fluorescent sensors. The sensors can have a variety of applications. They may be used in fundamental studies ranging from assay systems to locate the distribution and localization of membrane

bound receptors, transporter proteins and channels in whole assay systems. They may also be used in novel methodologies for the development of pharmaceutically active compounds using high throughput screening.

5 The small size of the of the nanocrystal ligand conjugate offers advantages over conventional techniques that use antibodies bound to fluorescent dyes. These advantages include the small size of the drug nanocrystal conjugate which enables it to fit into the synaptic gap. Antibody-fluorescent dye systems are much larger than the nanocrystal
10 drug conjugates of the present invention, so the antibody-fluorescent dye stems are less likely to fit into the synaptic gap. Additionally most antibodies are cell permeable.

 The increased photostability of the nanocrystals means that they are not as easily photo-bleached as conventional dyes. Therefore, the
15 nanocrystal compounds of the present invention may be used in experiments that require longer periods of illumination without photo-bleaching becoming a major problem.

 The increased brightness of the nanocrystals enhances the sensitivity of the assay systems when compared to traditional dyes.

20 Therefore, assay systems can be developed that detect lower concentrations of the analyte.

Also see "Quantum Dot Bioconjugates for Ultrasensitive
Nonisotopic Detection", Chan, Nie, Science, Vol. 281, 1998.

There are several patents that disclose nanocrystals that can be
5 used in connection with the present invention.

U.S. Patent No. 5,990,479 to Weiss et al. discloses a luminescent
nanocrystal compound that is capable of linking to an affinity molecule.
Weiss et al. further describe a process for making luminescent
semiconductor nanocrystal compounds and for making an organo
10 luminescent semiconductor probe comprising the nanocrystal compound
linked to an affinity molecule capable of bonding to a detectable
substance and a process for using the probe to determine the presence of
a detectable substance in a material.

U.S. Patent No. 5,751,018 to Alivisatos et al. discloses methods for
15 attaching semiconductor nanocrystals to solid inorganic surfaces, using
self-assembled bifunctional organic monolayers as bridge compounds.

U.S. Patent No. 5,537,000 to Alivisatos et al., which describes
electroluminescent devices formed using semiconductor nanocrystals as
an electron transport media and a method for making such
20 electroluminescent devices.


U.S. Patent No. 5,505,928 to Alivisatos et al. discloses
nanocrystals of III-V semiconductors, and U.S. Patent No. 5,262,352

Alivisatos et al. discloses a process for forming a solid, continuous thin film of a semiconductor material on a solid support surface.

5

10 Summary of the Invention

An embodiment of the present invention is to provide linker arms to attach organic compounds to nanocrystals, or quantum dots. A linker arm of the present invention may have the following formula:



n & p = 0-10
Z = O, CH₂, or NH

15

wherein Y represents the attachment point to the nanocrystal and
X represents the attachment point of an organic compound.

5 R is a bond or is selected from the group consisting of:

SH,

O(CH_{2(n)}O)_nSH,

NH(CH_{2(n)}O)_nSH,

NH(CH_{2(n)}NH)SH,

10 S(CH_{2(n)}O)_nSH, and

S(CH_{2(n)}S)SH. n is 1-10, with S being attached to the nanocrystal..

R₂ is a bond or selected from the group consisting of carbonyl, NH, S,
CONH, COO, S, C₁₋₁₀ alkyl, carbamate, and thiocarbamate.


15

When n and p are 1 or more, the resulting carbon or carbon chain may
be substituted.

Preferably, z is O. Preferably n and p are 1-5.

20

In another embodiment of the present invention, the linker arm
may have the following formula:



(1b)

- 5 Wherein Y is the attachment point for a nanocrystal, X is an attachment point of an organic compound.

R₂ is a bond or selected from the group consisting of

carbonyl,

O,

NH,

S,

CONH,

COO,

S,

C₁₋₁₀ alkyl,

carbamate, and

thiocarbamate.

R₃ is selected from the group consisting of:

SH,

O(CH_{2(n)}O)_nSH,

5 NH(CH_{2(n)}O)_nSH,

NH(CH_{2(n)}NH)SH,

S(CH_{2(n)}O)_nSH,


S(CH_{2(n)}S)SH, and

a polyether chain.


10 n is 1-10. S is attached to the nanocrystal.

Preferably, the organic compound is a biologically active compound. Examples of the biologically active compounds of the present invention include serotonin or serotonin derivatives, cocaine analogues,
15 phenyl tropane analogues, phenylisopropylamine derivatives, dopamine derivatives, melatonin derivatives, chlormethiazole derivatives, derivatives of RTI-4229-75, and derivatives of GBR 12935. RTI-4229-75 and GBR 12935 are further described below.


For the purposes of providing examples only, the preferred organic
20 compounds attached to the nanocrystal of the present invention specifically include the following:



Serotonin




Chlormethiazole derivative




Melatonin

5
10
T04350' 02.4360



RTI-4229-75




derivatives of GBR 12935

In the above examples, R represents the attachment point to the linker arm. Additionally, the R group may be “floating” when attached to the phenyl ring. That is, the R group may be attached to any available
5 carbon atom on the ring.

The present invention further is directed to nanocrystal compounds, which include linker arm derivatives of the present invention. More specifically, the nanocrystal compounds of the present invention comprise a semiconducting nanocrystal and a linking arm
10 having a first portion linked to the nanocrystal and a second portion linked to an organic compound.


Examples of nanocrystal compounds of the present invention include the following formulae (II), (III), (IV), (V), (VI), (VII), (X) and (XI):



(II)


n = 0-10

Preferably n is 2,3,4 or 5. The linker arm may be attached to positions
1,2,3, or 4. Most preferably, the linker arm is attached to position 2.



n = 0-10

Preferably n is 1, 2, 3, or 4 and the linker arm is attached to positions 1,
2, 3, or 4. Most preferably, positions 1, 2, or 3. Most preferably, position
2.




(IV)

$n = 0-10$

- 5 Preferably n is 1, 2, 3, 4 or 5 and the linker arm is attached to positions 1, 2, 3, or 4. Preferably, the linker arm is attached to one of positions 1, 2, or 3. Most preferably, position 3.

$X = \text{H}$ or halogen. Preferably, X is H or F.




(V)

$n = 0-10$

Preferably n is 2, 3, 4 or 5. The linker arm may be attached to positions


5 1, 2, 3, or 4. Preferably, position 2.



(VI)


$n = 0-10$

Preferably n is 2, 3, 4, or 5. The linker arm may be attached to positions 1 or 2. Preferably, position 2.



n = 0-10


Preferably n is 2, 3, 4 or 5. The linker arm may be attached to positions 1,2,3,or 4. Preferably, position 2.



$n = 0-10$


Preferably n is 2, 3, 4 or 5. The linker arm may be attached to positions

5 1, 2, 3, or 4. Preferably, position 2.




10 $n = 0-10$

Preferably n is 2,3,4 or 5. The linker arm may be attached to
 positions 1,2,3,or 4. Preferably, position 2.



$n = 0-10$

Preferably n is 2, 3, 4 or 5. The linker arm may be attached to positions 1, 2, 3, or 4. Preferably, position 2.



(XIII)

$n = 0-10$

- 5 Preferably n is 2,3,4 or 5. The linker arm may be attached to positions 1, 2, 3, or 4. Preferably, position 2.

The linker arm attaching the compounds to the nanocrystal can be altered by replacing the oxygen with sulfur or NH. The length of the alkyl substituent between the oxygen atoms may be increased or decreased and it may comprise of chains with lengths of 1 to 10 carbon atoms. Also the hetero atom in the chain may vary thus the chain may contain alternating NH and O functionalities or O and S functionalities.

Detailed Description of the Invention

As stated above, the present invention relates to linker arms to
5 which biologically active molecules can be attached to nanocrystals. The
nanocrystals used in conjunction with the present invention are the
nanocrystals typically used in fluorescent imaging techniques.

Preferably, the nanocrystals used in conjunction with the present
invention are semiconductor nanocrystals capable of luminescence
10 and/or scattering or diffraction when excited by an electromagnetic
radiation source (of broad or narrow bandwidth) or a particle beam, and
capable of exhibiting a detectable change of absorption and/or emitting
radiation in a narrow wavelength band and/or scattering or diffracting
when excited. For exemplary purposes, the nanocrystals of US 5,990,479
15 may be used with the present invention.

That is, in embodiments of the present invention, an organic or
inorganic single crystal particle having an average cross-section of about
20 nanometers (nm) or 20×10^{-9} meters (200 Angstroms), preferably no
larger than about 10nm (100 Angstroms) and a minimum average cross-
20 section of about 1nm, although in some instances a smaller average
cross-section nanocrystal, i.e., down to about 0.5nm (5 Angstroms), may
be acceptable. Typically the nanocrystal will have an average cross-

section ranging in size from about 1 nm (10 Angstroms) to about 10 nm (100 Angstroms).

Furthermore, for exemplary purposes only, these nanocrystals include, but not are limited to CdSe, CdS, PbSe, PbS, and CdTe.

5 As mentioned above, there are disadvantages to traditional dye molecules that are used in the area of fluorescent labeling. For example, simultaneous localization of several different proteins *in situ* is currently limited by the wide emission spectra and photostabilities of fluorescent dyes traditionally used to study cell surface receptors, ion channels, and
10 transporters. The nanocrystal compounds of the present invention can overcome the above deficiencies. For example, in one embodiment of the present invention, the nanocrystal compounds comprise core (CdSe)/shell(ZnS) semiconducting nanocrystals. Through quantum confinement, the fluorescent wavelength of these nanocrystals are
15 continuously tunable by size. For example a 25 Angstrom nanocrystal of this embodiment emits at 455nm while a 60 Angstrom nanocrystal of this embodiment emits at 625 nm. Unlike dye molecules and variants of green fluorescent protein, these nanocrystals have narrow gaussian emission spectra enabling multiplex imaging. The absorption of these
20 nanocrystals is continuous above the band-gap; hence all sizes of nanocrystals can be excited with a single excitation wavelength. In

addition, the nanocrystals of this embodiment are much brighter than traditional dyes, even hours after continuous illumination.

The present invention further relates to multiple organic compounds in combination with the linker arms of the present invention.

5 The present invention further relates to a method of attaching a linker arm to multiple organic compounds and a method of attaching a linker arm to a nanocrystal. The present invention further relates to the linker arms herein described and nanocrystals attached to the linker arms herein described. The present invention also relates to nanocrystals and
10 semiconductor nanocrystals in combination with the linker arms of the present invention. The present invention further relates to the attachment of a nanocrystal and a linker arm to an organic compound. The present invention relates to assay systems and assay kits for CNS research, receptor purification, pathogens, environmental contaminants,
15 toxins, and screening for drugs, insecticides, herbicides, and other biologically active substances.

The linker arms and linker arm compound derivatives of the present invention enhance stability and are relatively stable, including stability to biological degradation. The linker arms and the linker arm
20 compound derivatives of the present invention are also advantageous in that they can be synthesized at a relatively low cost.

More specifically, the present invention relates to linker arms such as, for example, ether-containing, polyether or carbon-carbon chain linker arms by which biologically active molecules such as CNS drugs and neurotransmitters can be attached to nanocrystals. The attachment of a linker arm of the present invention allows nanocrystals to be used as imaging agents in diverse applications such as biochemical research, CNS research, receptor purification, and high throughput screening for new drugs and other biologically active substances.

Additionally, the present invention relates to linker arms such as, for example, ether containing, polyether or carbon linker arm by which biologically active molecules such as drugs, hormones, etc. can be attached to nanocrystals. The linker arms of the present invention enhance water solubility of nanocrystals and allow nanocrystals to be attached to a diverse range of molecules ranging from drugs to polypeptides and neurotransmitters. The linker arm compounds of the present invention allow nanocrystals to be used as imaging agents in diverse applications such as CNS research, receptor purification, assay systems for pathogens, environmental contaminants, toxins, and a high throughput assay system for new drugs and biologically active molecules.

As stated above, preferably the organic part of the nanocrystal compounds of the present invention are biologically active compounds. Preferably, the biologically active compound is one that will bind to

detectable substances, if the substance is present, in the material being analyzed.

In general, any affinity molecule useful in the prior art in combination with a dye molecule to provide specific recognition of a detectable substance will find utility in the formation of the organo-luminescent semi conductor nanocrystal probes of the invention. Such affinity molecules include, by way of example only, such classes of substances as monoclonal and polyclonal antibodies, nucleic acids (both monomeric and oligomeric), proteins, polysaccharides, and small molecules such as sugars, peptides, drugs, and ligands. Lists of such affinity molecules are available in the published literature such as, by way of example, the "Handbook of Fluorescent Probes and Research Chemicals", (sixth edition) by R.P Haugland, available from Molecular Probes, Inc.

As stated above, the compounds of the present invention enable nanocrystals to be used as probes for neurotransmitters, receptors and transporter proteins. In one embodiment of the present invention, serotonin (5-hydroxytryptamine) is attached to a nanocrystal. Serotonin is a neurotransmitter which has been linked to the regulation of critical behaviors including sleep, appetite, and mood.

The serotonin transporter (SERT) is a 12-transmembrane domain protein responsible for the uptake of serotonin by the cell. The serotonin


labeled nanocrystal compounds of the present invention have a measurable ability to block the uptake of tritiated septonin by the human and *Drosophila* serotonin transporter (hSERT and dSERT).

Serotonin labeled nanocrystals (SNACs) of the present invention
5 may be prepared by reacting trioctylphosphineoxide coated nanocrystals with serotonin and tetramethylammonium hydroxide in methanol. The SNACs are isolated by precipitation and purified to remove serotonin. Linkage of the serotonin presumptively occurs through the lone pair of the hydroxyl to the Cd surface atoms of the nanocrystal. hSERT and
10 dSERT are transfected into HeLa cells via a vaccinia virus/T7 expression system. Following expression of the transfected transporters, the cells are assayed for uptake of tritiated serotonin in the presence of increasing concentrations of SNACs. K_i values, the concentration at which half the SNACs are bound to the transporter, are determined by nonlinear
15 regression. The values [K_i (hSERT) = 74uM, K_i (dSERT) = 29uM] indicate SNACs can effectively interact with the serotonin recognition site of the transporter.

These results suggest that highly fluorescent, serotonin labeled nanocrystals can be used as probes for SERT. These probes assist in
20 determining the structure of SERT, including the number of gene products (SERT proteins) that are required to assemble a functional unit, and following transporter movement within the cell.

The present invention enables nanocrystals to be used as imaging agents, which results in an assay system that is superior to traditional immunoassay systems because, among other things, several wavelengths can be used to induce fluorescence. The linker arm can be attached to a
5 number of different ligands, thus enabling them to be used in high throughput screening and receptor purification. The linker arm is stable and not as subject to enzymatic degradation as other linker arms may experience. The linker arm of the present invention also enhances the solubility of the nanocrystal, and can be readily derivitised. This enables
10 a wide range of molecules to be attached to the nanocrystals. The linker arm of the present invention is not as temperature sensitive as many immunoassay systems, and thus is likely to have a longer shelf life. Further, the linker arm of the present invention is also robust and therefore not susceptible to extremes of pH that may denature and
15 degrade peptide linkers.

As stated above, the linker arm of the present invention may have the following formula:



$n \text{ \& } p = 0-10$
 $Z = \text{O}, \text{CH}_2, \text{ or } \text{NH}$

wherein Y represents the attachment point to the nanocrystal and

5 X represents the attachment point of an organic compound.

R is a bond or is selected from the group consisting of:

SH,

$\text{O}(\text{CH}_2(n)\text{O})_n\text{SH}$,

10 $\text{NH}(\text{CH}_2(n)\text{O})_n\text{SH}$,

$\text{NH}(\text{CH}_2(n)\text{NH})\text{SH}$,

$\text{S}(\text{CH}_2(n)\text{O})_n\text{SH}$, and


$\text{S}(\text{CH}_2(n)\text{S})\text{SH}$. n is 1-10, with S being attached to the nanocrystal..

15 R_2 is a bond or selected from the group consisting of carbonyl, NH, S, CONH, COO, S, C_{1-10} alkyl, carbamate, and thiocarbamate.

When n and p are 1 or more, the resulting carbon or carbon chain may be substituted.

- 5 Preferably, z is O. Preferably n and p are 1-5.

In another embodiment of the present invention, the linker arm may have the following formula:



(1b)

Wherein Y is the attachment point for a nanocrystal, X is an attachment point of an organic compound.

- 15 R₂ is a bond or selected from the group consisting of
carbonyl,
O,

NH,
S,
CONH,
COO,
S,
C₁₋₁₀ alkyl,
carbamate, and
thiocarbamate.

R₃ is selected from the group consisting of:

SH,
O(CH_{2(n)}O)_nSH,
NH(CH_{2(n)}O)_nSH,
NH(CH_{2(n)}NH)SH,
S(CH_{2(n)}O)_nSH,
S(CH_{2(n)}S)SH, and
a polyether chain.

n is 1-10. S is attached to the nanocrystal.


Preferably, n is 1-5.

The length of the linker arms of the present invention may be increased or shortened in order to increase the solubility of the nanocrystal drug conjugate and increase the affinity of the ligand for its target protein.















- 5 The linker arms of the present invention include the following compounds:

10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100


FIG. 30









T. 04/23/00 08:44:36




T014230'0249800



104630-324980






Pub. No. 2004/0199850




In the above examples, R represents the point of attachment of an


5 organic compound.




The nanocrystal compounds of the present invention include the following examples, with S being the attachment point of the nanocrystal:







5





404230-8249860



5

Nanocrystal compounds of the present invention include compounds that comprise of nanocrystals with the following specific and preferred features: a CdSe core, ZnS shell, generally their cores are less than 25nm, in diameter. The surrounding ZnS shell is typically 10 to

20nm in thickness, and the ligand coated core shells are water solubilized by the addition of a mercapto acetic acid co-solubility ligand.

By attaching antibodies to nanocrystals via a linker arm of the present invention, nanocrystals can be made to bind to specific antigens.

5 Accordingly, an embodiment of the present invention is an assay kit developed for the detection of a diverse range of substances ranging from environmental contaminant such as DDT, dioxanes, chemical warfare agents, herbicides, pesticides, and pathogenic organisms such as Ecoli 0157 and Salmonela.

10 For example, the present invention comprises a process for treating a material, such as a biological material, to determine the presence of a detectable substance in the material. The process comprises contacting the material with a nanocrystal conjugated compound of the present invention, washing unbound nanocrystal conjugated compound away,
15 and exposing the material to energy such as an electromagnetic source or particle beam capable of exciting the nanocrystal conjugated compound of the present invention, and causing a detectable fluorescence to occur in the nanocrystal conjugated compound of the present invention. Thus enabling the location and distribution of a
20 particular substance within the biological material to be determined.

The nanocrystal compounds of the present invention may be used in the assays described in US Patent 5,990,479.


One assay system of the present invention is a high throughput fluorescence assay to identify novel ligands that might be effective antidepressants or ligands that might help combat cocaine addiction. In this assay a known agonist or antagonist for the dopamine receptor or transporter is bound to nanocrystals, and incubated with cells that either naturally express or have been engineered to express dopamine receptors or transporters. After incubating for 12 hours excess ligands are removed by washing and unknown compounds are incubated with the cells for a further 12 hours. The cells are washed again with buffer and a fluorescence assay is performed. Any cells that no longer fluorescence have a high affinity ligand bound to them and this ligand may be used as a lead compound for drug discovery. Such an assay system may be carried out in a conventional multiple well format system, such as the 96 well format.

Chart A, below demonstrates another method of the present invention that may be used to detect biologically active analytes. Chart A describes a sandwich assay system. In chart A, in step 1 monoclonal or polyclonal antibodies raised against a specific analyte or groups of analytes are bound to the surface of the plate. In step 2, the analyte is added and binds to the antibody. In step 3, the unbound analyte is washed away and a nanocrystal antibody conjugated using our linker arm of the present invention is added (once again poly or monoclonal

antibodies may be used). In step 3, the unbound nanocrystal antibody
conjugates are removed by washing, and a fluorescence assay is
performed to determine if the analyte is present in the sample being
analyzed and its concentration as a sample with a higher concentration
5 will produce a greater fluorescence. Multiple analytes can be screened for
using a conventional 96 well plate format.

10
"39449300"

(1)




Monoclonal or polyclonal antibodies raised against a specific analyte or group of analytes are bound to a surface.

5

Analyte is added



10




Analyte binds to the antibody.

15


Wash to remove unbound analyte and add our nanocrystal antibody conjugate

20



25

(3)




Wash to remove unbound nanocrystal antibody conjugate and perform fluorescence assay.

35



40



Polyethylene glycol linker arm

45

(4)




Chart A. NC = nanocrystal. A sandwich assay system.

The nanocrystal of the present invention may be used in affinity
5 chromatography, where a compound or biological molecule of interest
may be bound to a column. This may then be specifically labeled with the
antibody nanocrystal conjugate, substrate nanocrystal conjugate, or
drug nanocrystal conjugate of the present invention. The compound
could be a drug, a hormone, an enzyme, a protein, a nucleic acid or a
10 receptor. Once the nanocrystal conjugate has bound to the substrate of
interest, it may either remain bound to the column or be eluted with the
mobile phase. This would enable the isolation and identification of the
compound or biological molecule of interest. Unlike fluorescent dyes,
nanocrystals are not easily photo-bleached. Therefore, it would be easier
15 to watch the compound or compounds eluting off the column. Also such
a system may be applied to several different analytes enabling the
identification of several unknowns at once by using different sized
nanocrystals conjugated to different ligands. Thus it is theoretically
possible to identify different receptor classes or subtypes (e.g. 5-HT
20 receptor subtypes) as they elute off the column. For example it may be
possible to differentiate between 5HT2 and 5HT3 receptor subtypes using
such a system.

The linker arm acts as a spacer and separates the ligand from the nanocrystal thus possible steric and other interactions between nanocrystals and ligand are minimized. The linker arm may be an ethylene glycol moiety this helps to enhance the solubility in aqueous media. Many affinity chromatographic systems are typically run in such media. The polyether linker arm is also resistant to proteolytic cleavage which may be a problem with other assay systems.

Nanocrystals can be attached to enzymes via linker arms of the present invention. Thus the amino derived carboxylic acid derived polyethers may be linked to the backbone of the peptide via a peptide bond.


In this instance the linker arm removes the enzyme from the immediate environment of the nanocrystal. This may be important in reducing any effects that the nanocrystal may have upon the enzymes activity. Many such instances could be envisaged particularly if the enzyme or protein undergoes a conformational change during its catalytic cycle (e.g. Hemoglobin). Also the linker arm may increase the catalytic efficiency of the enzyme if the active site or sites are close to the enzymes surface.

Such a system may also be used to identify analytes in a similar manner to the nanocrystal antibody conjugates previously described. It may also be used in high throughput screening where the compounds of

interest are bound to wells in plates and the enzyme nanocrystal conjugate is added. An example of this is shown in chart B below:

5

Compounds A,B,C and D etc are bound to wells on a plate.



30 Chart B identifying active compounds in a high throughput assay system

The enzymes substrate or inhibitor may also be bound to the
 35 polyethylene glycol nanocrystal conjugate. In this instance, the linker
 arm of the present invention reduces steric hindrance between

nanocrystal and enzyme and it enables the substrate to enter the enzymes catalytic or allosteric site, which may not be possible if the substrate were bound to the surface of the nanocrystal (particularly if the site of interest is deep within the enzyme). An assay system that could

5 use this technique as a tool for identifying new drugs is outlined in chart C, below, where compounds that will compete for the site of interest can be identified. If the nanocrystal is bound to an inhibitor via the linker arm of the present invention it is likely that this assay system could also be used to identify other inhibitors of the enzyme.

10 Chart C:

T. 03/25/03 08:24:33




Chart C.

35 F,J,X and Z are new chemical entities bound to nanocrystals via our linker arm.
 Inactive compounds will not bind and will be washed away thus we have an assay
 system for detecting novel active compounds.

40 One specific substance may also be bound to the nanocrystal (e.g.
 a substrate for the enzyme) and a simple competitive assay could be
 performed with unknown substances in a manner similar to that shown

above in chart C. Any substance that has a higher affinity for the site of interest on the enzyme, protein or receptor than the ligand conjugated nanocrystal would displace the ligand conjugated nanocrystal resulting in a loss off fluorescence, thus enabling this system also to be used as a high throughput assay system as well as an analytical tool for environmental contaminates, toxins, and other unknowns.

This system can be applied to receptors rather than enzymes. In this case, the nanocrystal is bound to an agonist, antagonist, or natural ligand for the receptor (e.g. Seratonin). This system could be used as an assay system for receptor agonist or antagonist. It would be of interest in neuropharmacology where receptor location and distribution could be mapped. By attaching different sized nanocrystals to different agonists, antagonists, or ligands it may be feasible to develop multiplexing assay systems, thus enabling the effects of drugs and other neurologically active agents to be monitored in whole cell assay systems. Assaying the location and distribution of many membrane bound receptors and transporter proteins is currently difficult using conventional antibody fluorescent dye systems is difficult due to photo-bleaching and the broader emission spectra of dyes.

Nanocrystals may be attached to DNA or RNA via the linker arm of the present invention. In this case, the major role of the linker arm acts as a spacer and reduces steric hindrance. The DNA or RNA conjugates

may be used as a tool in molecular biology for identifying the location and frequency and rate of expression of specific gene sequences. Such a system is outlined in chart D, below:

5

A C A A C C T A G

10

Incubate DNA or RNA with our strand of labeled RNA or DNA that is conjugated to A nanocrystal via the linker arm. Then wash. The sections of the DNA or RNA of interest will bind to our probe.

15

Linker arm

NC

20

25

A C G T T G G T A G

30

Thus the distribution and location of genes can be shown also the frequency of the gene in DNA or RNA can be measured.

Chart D.

The nanocrystal conjugates of the present invention can also be used in assay systems in the same manner that antibody fluorescent dye conjugates, radio immuno assays, and ELISA are used. Examples of the assay system include routine assays used in medical laboratories such as tests for various disease states for example HIV, Diabetes, etc.

Other features of the invention will become apparent in the course of the following examples which are given for illustration of the invention and are not intended to be limiting thereof.

Examples

Ligands That Comprise of a Biologically Active Molecule

Two synthetic routes have been developed for the production of a serotonin derivative with a polyether linker arm attached to it. These routes are outlined in charts 1, 2, and 3. Route B is a variant of Route A in which the protecting group is changed to a phalimido substituent.

Preparation of the linker arm







Chart 1:

(i) 2-(2-(2-Chloroethoxy)ethoxy)ethanol, Sodium, ethanol, paramethoxy- α -toluene thiol, reflux 24 hours; (ii) 1, pyridine, para-toluene sulfonyl chloride, stir at room temperature for 24 hours.



5







Chart 2. Method A

(i) Serotonin creatin sulfate monohydrate, di-tertiarybutyl dicarbonate, potassium carbonate; (ii) 2, 3, Potassium carbonate (60 equiv), acetone, reflux 168 hours; (iii) 5, trifluoro acetic acid, room temperature, 2 hours; (iv) 5, Mercury(II) acetate, trifluoro acetic acid, hydrogen sulfide.

5

704250-8249860



04250-024360




Chart 3. Method B

(i) Serotonin creatine sulphate monohydrate, N-Carboxyphthalimide;
(ii) 7, 2, CsCO₃ (3 equivalents) reflux 24 hours; (iii) Hydrazine hydrate

(iv) Mercury(II) acetate, H₂S

The following compounds correspond with the compounds in charts 1, 2 and 3 above.

5 8-(4-methoxybenzylthio)-3,6-dioxaoctanol (1)

Sodium metal (0.8g, 34.8 mmols) is added to ethanol (100ml) in a 250ml round bottomed flask equipped with a reflux condenser and a stirrer. 4-Methoxy- α -toluenethiol (4.88ml, 34.8 mmol) is added upon complete reaction of the sodium with the ethanol. The mixture is stirred at room temperature for 30 minutes then

2-(2-(2-chloroethoxy)ethoxy)ethanol (5.88g, 34.8 mmols) is added. The reaction mixture is heated at reflux for 24 hours. After cooling to room temperature it is poured into saturated ammonium chloride solution (40ml) and extracted into dichloromethane (3x100ml). The

dichloromethane solution is dried over magnesium sulfate and yields a yellow oil upon evaporation. The product is purified using column chromatography on silica eluted with a gradient system from dichloromethane to dichloromethane: methanol 10% to give approximately 7.24g (71%) of the product as a yellow oil.

8-(4-Methoxybenzylthio)-3,6-dioxaoctyl tosylate (2)

5 8-(4-methoxybenzylthio)-3,6-dioxaoctanol (7.24g, 25 mmols) is
added to dry pyridine (5ml) and cooled to 0°C under nitrogen in a 100ml
flask equipped with a stirrer. Para-toluene sulphonyl chloride (6.5g, 34
mmol) is slowly added to this solution and the mixture is stirred and
allowed to warm to room temperature. It is stirred at room temperature
10 for 18 hours after which it is added to water (100ml) and
dichloromethane (100ml). The organic layer is separated and washed
with hydrochloric acid (2N, 1x50 ml) and saturated sodium bicarbonate
solution (50ml). It is dried over magnesium sulfate, filtered and
evaporated. The crude product is obtained as a red oil and this is
15 purified using column chromatography, in which the crude material is
adsorbed onto silica and the column is eluted with a gradient system
running from 20% diethyl ether: petroleum ether to 70% diethyl ether:
petroleum ether. This yields approximately 8.00g (72%) of the product as
a yellow oil.

3-[2-N-(tert-Butoxycarbonyl)amino]1H-indole-5-ol (3)

This compound is prepared as previous described in the Journal of medicinal chemistry 1996, 39, 314, Glennon R., et al. Potassium carbonate (1.3g, 9.5 mmols) is added all at once to a suspension of serotonin creatine sulfate monohydrate (1.9g, 4.7 mmols) dissolved in water (24ml), in a 100ml flask equipped with a stirrer. When the materials have dissolved di-tertbutyl dicarbonate (1.01g, 4.7 mmols) is added. The mixture is left stirring at room temperature for 24 hours. The product is extracted with ethyl acetate (3x20ml). The combined organic extracts are washed with water (1x20ml), hydrochloric acid (5%, 15ml) and brine (15ml). The organic solution is dried over magnesium sulfate and the crude product is obtained as a black tar upon evaporation. The product is purified using column chromatography on silica gel eluted with dichloromethane. This yields approximately 1.34g (100%) of the product as a pale yellow oil.

1-[3-[2-[N-(tert-Butoxycarbonyl)amino]ethyl]-1H-indol-5-yl]oxy-3,6-dioxo-8-(4-methoxybenzylthio)octane (4)

8-(4-Methoxybenzylthio)-3,6-dioxaoctyl tosylate (2.82g, 6.4 mmols) is added to acetone (100ml). 3-[2-N-(tert-Butoxycarbonyl)amino]1H-indole-5-ol (1.76g, 6.4 mmols) is dissolved in acetone (20ml) and the two solutions are

combined in a 250ml flask equipped with a reflux condenser and a stirrer. Dry potassium carbonated (60g) is added and the mixture is left refluxing for 168 hours. Upon cooling the solution is filtered and evaporated. The product is purified using column chromatography on silica gel eluted with a gradient system running from dichloromethane to 90% dichloromethane: methanol. This gave 1.9g (60%) of the product as a yellow oil.

1-[3-[2-aminoethyl]-1H-indol-5-yloxy]-3,6-dioxa-8-(4-methoxybenzylthio)
octane (5)

Method A:

1-[3-[2-[N-(tert-Butoxycarbonyl)amino]ethyl]-1H-indol-5-yloxy]-3,6-dioxa-8-(4-methoxybenzylthio)octane (0.8g, 1.5 mmols) is dissolved in toluene (60ml) in a 250ml round bottomed flask equipped with a stirrer. Trifluoro acetic acid (20ml) is added and the mixture is stirred at room temperature for 2 hours. It is evaporated under reduced pressure and the product is purified using silica gel chromatography eluted with triethylamine 3%: methanol 5%: dichloromethane 92%. This yields approximately 0.6g (92%) of the product (5) as a pale yellow oil.

Method B:

1-[3-[2-[N,N-Phtalimido]ethyl]-1H-indol-5-yloxy]-3,6-dioxa-8-(4-methoxybenzylthio) octane (1.4g, 2.4 mmols) is dissolved in absolute ethanol (50ml) in a 100ml round bottomed flask equipped with a stirrer. Hydrazine mono hydrate (2ml) is added and the solution is stirred for 18 hours at room temperature and then evaporated. Dichloromethane (50ml) is added to the resulting tar and the mixture is heated at reflux for 30 minutes. After cooling it is filtered and evaporated and 7 was purified using silica gel column chromatography eluted with dichloromethane 95%: triethylamine 3%: methanol 2%. This yields approximately 0.6g (51%) of the product (5) as a pale yellow oil.

1-[3-[2-amino ethyl]-1H-indol-5-yloxy]-3,6-dioxa-8-mercapto octane (6)

1-[3-[2-aminoethyl]-1H-indol-5-yloxy]-3,6-dioxa-8-(4-methoxybenzylthio) octane (0.6g, 1.4 mmols) is dissolved in trifluoroacetic acid (15ml) and cooled to 0°C in a 50ml round bottomed flask equipped with a stirrer. Anisole (1.5ml) and mercury (II) acetate (0.516g, 1.6 mmols) are added and the mixture is stirred at 0°C for 2 hours. The solution is evaporated and the resulting solid is washed with diethyl ether (3x50 ml). After air drying the solid is dissolved in glacial acetic acid (25ml) and hydrogen sulfide is bubbled through the solution for 30 minutes. Mercuric sulfide is removed by filtration and the solution is evaporated to dryness. The resulting oil is dissolved in dichloromethane and washed with sodium bicarbonate solution (1M, 1x20 ml). The solution is dried over

magnesium sulfate and evaporated. This yields approximately 0.072g (39%) as a pale yellow oil.

N,N-Phthalimido-2-(5-hydroxy-1H-indole-3-yl)ethylamine (7)

5

This compound is prepared using the method that has previously been described in the Journal of medicinal chemistry 1996, 39, 4717 Barf T., et. al. To a stirred solution of serotonin creatine sulphate monohydrate (3.8g, 9.4 mmols) in water (15ml) and tetrahydrofuran (15ml), is added a solution of 10% sodium bicarbonate until a pH of 8 is obtained.

10

N-Carboxyphthalimide is added and the mixture is stirred at room temperature overnight. The resulting solid is removed by filtration and it is recrystallized from absolute ethanol, to give 2.5g (87%) of product as a yellow solid. Mp 215-216 °C (lit 213-216 °C).

15

1-[3-[2-[N,N-Phthalimido]ethyl]-1H-indol-5-yl]oxy]-3,6-dioxo-8-(4-methoxybenzylthio)octane (8)

20


8-(4-Methoxybenzylthio)-3,6-dioxaoctyl tosylate (1.6g, 3.6 mmols) is added to acetone (100ml) then N,N-Phthalimido-2-(5-hydroxy-1H-indole-3-yl)ethylamine (1g, 3.3 mmols) is added. Dry Cesium carbonate (3g, 3 equivalents) was added and the mixture is heated at reflux for 24 hours. The

solution is cooled to room temperature and filtered. The product (8) is purified using silica gel eluted with dichloromethane 98%: methanol. This gives approximately 1.1g of (8) as a pale yellow oil.

5

Attaching the linker arm to alkyl alcohols

The linker arms of the present invention may be attached to alkyl alcohols via an ether linkage. Many drugs, DNA, RNA, glycoproteins, intracellular messengers and hormones such as the steroids contain these functionalities. By way of an example a derivative of the neuroprotective agent chlormethiazole (9) has been synthesized.



(9)

A synthesis of the derivative of chlormethiazole is outlined in chart 4, below.

5




Chart 4. (i) 4-methyl-5-thiazoleethanol, 2, KOH, tertiary butyl ammonium chloride;

10 (ii) Mercury(II) acetate, trifluoroacetic acid, Hydrogen sulfide.

2-[2-[2-[2-(4-Methyl-thiazol-5-yl)-ethoxy]ethoxy]ethoxy]thioethyl-
(4-methoxybenzyl)ether (10)

5

4-methyl-5-thiazoleethanol (1.5ml, 13.2 mmols) is added to
dichloromethane (50ml). Potassium hydroxide (4g) dissolved in water
(4ml) and tertiary butyl ammonium chloride (0.02g) are added. 8-(4-
Methoxybenzylthio)-3,6-dioxaoctyl tosylate (1.8g, 4.4 mmols) is dissolved
on dichloromethane and added to the mixture. The mixture is heated at
reflux for 240 hours and then cooled to room temperature. Water (20ml)
is added, the organic layer is separated and dried over magnesium
sulfate.

15

After removing the magnesium sulfate by filtration the solvent is
removed under reduced pressure. The product is purified using column
chromatography on silica gel eluted with ethyl acetate 99%: methanol.
This yields approximately 0.33g (20%) of the product as a pale yellow oil.

20

2-[2-[2-[2-(4-Methyl-thiazol-5-yl)ethoxy]ethoxy]ethoxy]ethanethiol (11)


2-[2-[2-[2-(4-Methyl-thiazol-5-yl)-ethoxy]ethoxy]ethoxy]thioethyl-

(4-methoxybenzyl)ether (0.33g, 0.9 mmols) is dissolved in trifluoroacetic acid (10ml) and cooled to 0°C. When the solution is at a temperature of 0°C mercury (II) acetate (0.3g, 0.9 mmols) and anisole (1ml) are added and the mixture is stirred at 0°C for 2 hours. The solvent is evaporated under reduced pressure and the mercury salt is triturated with diethyl ether (3x50ml). The resulting solid is dissolved in glacial acetic acid (20ml) and hydrogen sulfide is bubbled through the solution for 30 minutes. After which the solution is filtered and evaporated under reduced pressure. The product is purified via column chromatography on silica gel eluted with dichloromethane 99%: methanol. This yields approximately 0.02g (8%) of the product as a colorless oil.

Alteration of linker arm to attach aryl and
alkyl amines via an amide linkage

The polyethylene glycol linker arm can be altered so that it can be attached to aryl and alkyl amines via an amide linkage. The derivative of the linker arm can be readily prepared and a synthetic scheme for the derivative is outlined in chart 5, below.

5




10 Chart 5.


(i) CrO_3 , H_2SO_4 ; (ii) Na, ethanol, paramethoxy- α -toluene thiol, reflux 24 hours;
 (iii) Oxalyl chloride, DMF

15 The resulting carboxylic acid (13) can be attached to amines using a variety of reagents such as DCC or by making the acid chloride (14).

Two such derivatives that we have synthesized are the derivative of the cocaine analogue RTI-4229-75 (15) and the derivative of GBR 12935 (16):



(15)



(16)

710250 324388

5

10

5

The synthesis of these compound are outlined in charts 6, 7 and 8, below. The linker arm derivative that contains this carboxylic acid functionality may also be attached to proteins and antibodies via an amide bond, alternatively it may be attached to RNA and DNA via a ester linkage to the ribose or deoxy ribose moiety.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100










Chart 6.

(i) 16, triethylamine, dichloromethane; (ii) trifluoroacetic acid, mercury
(II) acetate, glacial acetic acid, hydrogen sulfide



7.044230" 92.449863





5

Chart 7.

(i) Mg, diethyl ether; (ii) 2-Chloroethanol, sulfuric acid;
(iii) piperazine hexahydrate, potassium carbonate; (iv) H₂SO₄, HNO₃;
(v) Oxalyl chloride, DMF, triethylamine; (vi) AlH₃; (vii) SnCl₂, CH₃CH₂OH

5




Chart 8.

(i) oxalyl chloride, DMF, dichloromethane, tetrahydrofuran, reflux 48 hours, silica, oxalic acid

5 2-(2-(2-Chloroethoxy)ethoxy)ethanoic acid (12)

2-(2-(2-chloroethoxy)ethoxy)ethanol (1.69g, 10 mmols) is dissolved in acetone (50ml). This solution is added drop wise to a solution of sulfuric acid (1.5M, 60ml) containing chromium (VI) oxide (5.79g, 38 mmols) at 0°C. Upon complete addition of the alcohol the solution is allowed to warm to room temperature for 18 hours. Inorganic chromium salts are removed by filtration and the solution is concentrated under reduced pressure. The crude product is extracted from solution using dichloromethane (3x100ml) and the combined extracts were dried over magnesium sulfate. After filtration and evaporation under reduced pressure the crude product is obtained as a colorless oil 1.7g (93%). This is used without further purification.

8-(4-Methoxybenzylthio)-3,6-dioxaoctanoic acid (13)

20 Sodium (0.253g, 11 mmols) is added to absolute ethanol (50ml) and stirred at 0°C for 30 minutes. 4-Methoxy- α -toluenethiol (0.78ml, 6 mmols) is added and the mixture is stirred at room temperature for 30

minutes. 2-(2-(2-Chloroethoxy)ethoxy)ethanoic acid (1g, 5.5 mmols) is added and the mixture is heated at reflux for 18 hours. It is cooled to room temperature poured into distilled water (100ml) and acidified with hydrochloric acid (2M, 1X50 ml). The product is extracted with
5 dichloromethane (2X100ml) and the organic solution is dried over magnesium sulfate. After filtering the organic solution it is evaporated under reduced pressure. The product is purified using column chromatography on silica eluted with a gradient system running from dichloromethane to dichloromethane 90%: methanol. This gives
10 approximately 1.24g (94%) of the product as a colorless oil.

1-[2-[bisphenylmethoxy]ethyl]-4-(3-(4-aminophenyl)propyl)piperazine (16)

1-[2-[bisphenylmethoxy]ethyl]-4-(3-(4-nitrophenyl)-1-oxopropyl)piperazine
15 (0.9g, 2.8 mmols) is dissolved in absolute ethanol (10ml) in a 100ml round bottomed flask equipped with a stirrer and reflux condenser. Tin (II) chloride dihydrate (2.6g) is added and the mixture is heated at reflux for 90 minutes. The solution is poured into crushed ice and a solution of sodium carbonate (5%) in water is added until a pH of 8 is obtained. The aqueous solution is extracted
20 with ethyl acetate (3x200ml) and this is dried over magnesium sulfate. The product is purified using column chromatography on silica gel eluted with

ethylacetate 92%: methanol 5%: triethylamine. This gives approximately 0.66g (78.6%) of the product as a pale yellow oil.

5

3-(4-Chlorophenyl)-8-methyl-8aza-bicyclo[3.2.1]octane-2-carboxylic acid

2-[4-(2-{2-[2-(4-

methoxybenzylthio)ethoxy]ethoxy}acetylamino)phenyl]ethyl ester (17)

8-(4-Methoxybenzylthio)-3,6-dioxaoctanoic acid (0.008g, 0.027

mmols) is dissolved in dry toluene (10ml), oxalyl chloride (0.0008ml is added and then dry dimethyl formamide (1 drop).The mixture is stirred

at room temperature for 1 hour and then evaporated to yield crude 8-(4-Methoxybenzylthio)-3,6-dioxaoctonyl chloride (14). The 8-(4-

Methoxybenzylthio)-3,6-dioxaoctonyl chloride (14) is dissolved in dry dichloromethane (20ml), 3β-(p-Chlorophenyl)tropane-2β-carboxylic acid p-aminophenylethyl ester (0.0100g, 0.025 mmols) and triethylamine (2

drops) are added. The mixture is heated at reflux for 18 hours cooled and evaporated under reduced pressure. (17) is purified using column

chromatography on silica gel eluted with ethyl acetate 98%: triethyl amine. This yields approximately 0.006g (34%) of (17) as a tar.

3-(4-Chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid

5 2-(4-{2-[2-(2-mercaptoethoxy)ethoxy]acetylamino}phenyl)ethyl ester (18)

10 3-(4-Chlorophenyl)-8-methyl-8aza-bicyclo[3.2.1]octane-2-
carboxylic acid

2-[4-(2-{2-[2-(4-

methoxybenzylthio)ethoxy]ethoxy}acetylamino)phenyl]ethyl ester

(0.021g, 0.03 mmols) is dissolved in trifluoroacetic acid (5ml) and cooled

15 to 0°C. Anisole (0.05ml) and mercury (II) acetate (0.011g, 0.036 mmols)

are added to this solution and it is stirred at 0°C for 2 hours. The solvent

is evaporated, the product is triturated with diethyl ether and vacuum

dried. Then it is dissolved in glacial acetic acid (10ml) and hydrogen

sulfide is bubbled through the solution for 30 minutes. The solution is

20 filtered evaporated and methanolic hydrogen chloride (10ml) is added to

the tar. Then it is evaporated under reduced pressure and this procedure

USPTO Case 2:13-cv-00000

is repeated 5 more times. After drying under vacuum 0.008g (44%) of (17) is obtained as the hydrochloride salt.

Diphenylmethanol (19)

5

This compound was synthesised using the method reported in the Journal of the Chemical Society, 1960, 2133, by Mole. A 1 litre three necked round bottomed flask equipped with a stirrer a reflux condenser and a 200ml pressure equalising addition funnel, is charged with magnesium turnings (15.36g, 630 mmols). Dry diethyl ether (150ml) and iodine (0.1g, 0.3 mmols) are added. The mixture is heated at reflux until the purple iodine colour disappeared and to this solution was added 5ml of a solution of bromo benzene (65.2ml, 97.24g, 620 mmols) in 150ml of anhydrous ether. The reaction mixture is heated at reflux until a cloudy grey color forms. The heat is removed and the remaining bromo benzene is added drop wise at such a rate so as to maintain reflux. The solution is heated at reflux for a further hour after the addition of bromobenzene is complete. After which it is cooled to 10°C in an ice acetone bath and benzaldehyde (60ml, 62.4g, 588 mmols) in anhydrous ether 200ml is added drop wise so that the temperature of the reaction mixture does not exceed 20°C. The reaction mixture is allowed to warm to room temperature after the addition of benzaldehyde and it is stirred at room temperature for a further 18 hours. The reaction is quenched by adding ammonium chloride solution

(100ml) at 0°C. After which the organic layer is separated washed with water and dried over magnesium sulfate. The solution is filtered and evaporated and the product is washed with hexanes (150ml) to give approximately 51.6g (45%) of the product as a colorless solid mpt = 64 – 64.5°C.

5

1,1'-[(2-Chloroethoxy)methylene]bis-benzene (20)

This compound was synthesized using the method reported in the European Journal of Medicinal Chemistry, 1980, 15 (4), 363, by Van Der Zee P. et. al. Freshly distilled 2-chloroethanol (11g) is added to toluene (25ml) in a 500ml round bottomed flask, equipped with a reflux condenser a 200ml pressure equalizing funnel and a stirrer. Concentrated sulphuric acid (1ml) is added and the mixture is heated at reflux for 5 hours during which Diphenylmethanol (11,56g, 90 mmols) dissolved in toluene (150ml) is added drop wise. Then the solution is cooled to room temperature the aqueous layer is separated and the organic solution is washed with sodium bicarbonate (sat, 100ml) and water (2 x 100ml). It is dried over magnesium sulphate filtered and evaporated. The product is purified by vacuum distillation and this gives approximately 6g (26%) of the product as a colorless oil.

20

1-[2-[bisphenylmethoxy]ethyl]piperazine (21)

Piperazine hexahydrate (47g, 240 mmols) is added to toluene (100ml) and anhydrous potassium carbonate (66g, 600 mmoles) is added. The mixture is
5 heated at reflux and
1,1'-[(2-Chloroethoxy)methylene]bis-benzene (20g, 80 mmols) is added drop wise over five hours. After refluxing for a further 18 hours the solution is allowed to cool to 70°C washed with water (5 x 250ml), dried over magnesium sulfate, filtered and evaporated. The resulting yellow oil is converted to a dimaliate salt
10 by crystallising from diethyl ether. This gives approximately 25g (50%) of the product as a colourless solid.

Para-Nitrohydrocinnamic acid (22)

15 This compound is prepared using the method described by Moloney in the journal of medicinal chemistry, 1999, volume 42 No 14 page 2504.

Hyrocinnamic acid is added to concentrated sulfuric acid (49ml) in a 3 necked 250ml round bottomed flask equipped with a stirrer and thermometer. The flask is cooled to 0°C in an ice bath and concentrated nitric acid (10ml) is added
20 drop wise maintaining the temperature below 10°C. The solution is stirred for a further hour at 0°C after the complete addition of the nitric acid. Then the ice bath is removed and the mixture is stirred at room temperature for 30 minutes.

The resulting orange solution is poured into ice and the crude product is collected by filtration. The product is air dried and re-crystallised from ethyl acetate giving approximately 10g (29%) of the para-nitrohydrocinnamic acid as a colorless solid.

5

1-[2-[bisphenylmethoxy]ethyl]-4-(3-(4-nitrophenyl)-1-oxopropyl)piperazine (23)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201

1-[2-[bisphenylmethoxy]ethyl]-4-(3-(4-nitrophenyl)propyl)piperazine (24)

1-[2-[bisphenylmethoxy]ethyl]-4-(3-(4-nitrophenyl)-1-oxopropyl)piperazine
5 (5g, 14.8 mmols) in a 250ml round bottomed flask equipped with a stirrer and a
reflux condenser is dissolved in dry THF (100ml). Alane in toluene (0.5M, 59ml)
is added and stirred at room temperature for 30 minutes. The reaction is
quenched with sodium hydroxide solution (10%, 200ml). The aqueous solution
is extracted with diethyl ether (3x150ml), dried over magnesium sulfate filtered
10 and evaporated. The product is purified using silica gel chromatography eluted
with a gradient system eluted with ethyl acetate 90%: methanol to ethyl acetate
87%: methanol 10%: triethylamine. This gives approximately 3.35g (68%) of the
product as a pale yellow oil.

15 N-(4-(3-[4-(2-Benhydryloxyethyl)piperazine-1-yl]propyl)phenyl)-2-[2-(2-
mercaptoethoxy)ethoxy] acetamide (25)

8-(4-Methoxybenzylthio)-3,6-dioxaoctanoic acid (0.6g, 2.2 mmols) is
dissolved in dry toluene (50ml) under nitrogen in a 100ml round bottomed flask
20 equipped with a stirrer and a reflux condenser. Oxalyl chloride (0.5ml) and a
catalytic quantity of dimethyl formamide (1 drop) are added. The solution is
stirred at room temperature for 2 hours, then evaporated under reduced

pressure. The resulting crude 8-(4-Methoxybenzylthio)-3,6-dioxaoctonyl chloride (14) is dissolved in dry dichloromethane (100ml) in a 250ml round bottomed flask equipped with a reflux condenser and a stirrer. 1-[2-[bisphenylmethoxy]ethyl]-4-(3-(4-aminophenyl)propyl)piperazine (0.66g, 2.2 mmols) in dry tetrahydrofuran and triethylamine (5ml) are added and the mixture is allowed to reflux under nitrogen. Then the solvent is evaporated and the product is columned on silica eluted with ethyl acetate 93%: methanol 5%: triethylamine. The crude product is converted to the oxylate salt by dissolving it in methanol (50ml) and adding oxalic acid (1g) dissolved in methanol (20ml). The resulting solid is left standing at room temperature for 18 hours and removed by filtration. The oxalate salt is converted back to the base and the product is purified by column chromatography on silica eluted with a gradient system running from dichloromethane (90%): methanol to dichloromethane (87%): methanol 10%: triethylamine. This gives the product as a yellow oil it is converted back to the oxylate salt, as described above and this is filtered and air dried. To yield approximately 0.28g (28.9%) of the product as a yellow solid.

Varying the length of the linker arm

5

The length of the linker arms of the present invention may be changed. Accordingly, at least a di and tetra polyethylene glycol linker arm may be synthesised. The synthetic routes for these compounds are outlined in charts 9 and 10, below. The linker arm is shortened in chart 9 and lengthened in chart 10.






Chart 9.

- 15 (i) Sodium, ethanol, paramethoxy- α -toluene thiol, reflux 24 hours;

(ii) pyridine, para toluene sulphonyl chloride, stir at room temperature for 24 hours.

5



10

Chart 10.

(i) thionyl chloride; (ii) Sodium, ethanol, paramethoxy- α -toluene thiol, reflux 24 hours; (iii) pyridine, para-toluene sulfonyl chloride, stir at room temperature for 24 hours.

15

5 5-(4-methoxybenzthio)-3-oxapentanol (26)

Sodium metal (0.92g, 40 mmols) is added to absolute ethanol
(100ml) at 0°C.

4-methoxy- α -toluenethiol (5.6ml) is added after the sodium has
10 completed reacting.

2-(2-chloroethoxy)ethanol (5.48g, 44 mmols) is added 30 minutes later
and the mixture is heated at reflux for 18 hours. The solution is cooled to
room temperature and added to saturated ammonium chloride solution
(100ml). It is extracted into dichloromethane (3x100ml). After drying the

15 combined organic extracts over magnesium sulfate and filtering, the
dichloromethane is removed under reduced pressure. The product is
purified by column chromatography on silica gel eluted with a gradient
system from dichloromethane to dichloromethane 90%: methanol. This
yields approximately 5.9g (60%) of the product as a colorless oil.

20

5-(4-Methoxybenzylthio)-3-oxapentyl tosylate (27)

5-(4-Methoxybenzylthio)-3-oxapentanol (26), (2.42g, 10 mmols) is added to dry pyridine (10ml) and cooled to 0°C, para-toluene sulfonyl chloride (2.59g, 14 mmols) is added and the mixture is allowed to warm to room temperature over an 18 hour period with stirring. Water (50ml) and dichloromethane (100ml) are added. The organic layer is separated, it is washed with hydrochloric acid (2M, 1x100ml) and water (50ml). The organic solution is dried over magnesium sulfate, filtered and evaporated. The product is purified using column chromatography on a silica column eluted with a gradient system from petroleum spirit 70%: diethyl ether to petroleum spirit 30%: diethyl ether. This yields approximately 0.13g (3.6%) of the product as a colorless oil.

2-(2-(2-(2-Chloroethoxy)ethoxy)ethoxy)ethanol (28)

Tetraethylene glycol (192g, 990 mmols) is added to dry chloroform (200ml) in a 1L flask equipped with a stirrer, reflux condenser and a thermometer. Dry pyridine (80ml) is added to this solution and it is cooled to 0°C. Freshly distilled thionyl chloride (73ml) is added over a 4 hour period, whilst maintaining the temperature below 10°C. After all the

thionyl chloride has been added the solution is heated at reflux for 18 hours. Then the chloroform is removed under reduced pressure and the resulting residue is extracted with water (2x100ml). The aqueous solution is washed with hexane's (2x100ml) and the crude product is
5 extracted into toluene (5x100ml). Then the solvent is dried with magnesium sulfate filtered and evaporated. The product is purified by distillation under reduced pressure using an aspirator (Bpt = 140-160°C). This yields approximately 19.8g (9.4%) of the product as a colorless oil.

10
11-(4-Methoxybenzylthio)-3,6,9-trioxaundecanol (29)

Sodium metal (0.8g) is added to absolute ethanol (100ml) at 0°C in a 250ml round bottomed flask equipped with a stirrer and a reflux
15 condenser. After the sodium has completely reacted with the ethanol 4-methoxy- α -toluenethiol (4.9ml) is added. This is stirred at room temperature for 30 minutes.

Then 2-(2-(2-(2-Chloroethoxy)ethoxy)ethoxy)ethanol (7.4g, 34 mmols) is added and the mixture is heated at reflux for 18 hours. After cooling to
20 room temperature it is added to saturated ammonium carbonate solution (100ml) and extracted into dichloromethane (3x100ml). The combined organic extracts were dried over magnesium sulfate filtered and

evaporated. The product is purified by column chromatography on silica gel eluted with a gradient system from dichloromethane to dichloromethane 90%: methanol. This yields approximately 6g (53%) of the product as an oil.

5

11-(4-Methoxybenzylthio)-3,6,9-trioxaundecanyl tosylate (30)

10



2-(2-(2-(2-Chloroethoxy)ethoxy)ethoxy)ethanol (5.9g, 18 mmols) is dissolved in dry pyridine (10ml) and cooled to 0°C, in a 50ml round bottomed flask equipped with a stirrer and a calcium chloride drying tube. Para-toluene sulfonyl chloride (4.66g, 24 mmols) is added to the mixture and it is stirred for 18 hours, during this period the temperature of the reaction mixture is allowed to increase from 0°C to room temperature. Water (50ml) is added to the reaction mixture and it is extracted with dichloromethane (2x50ml). The combined organic extracts are washed with hydrochloric acid (2M, 2x50ml), saturated sodium bicarbonate solution (2x50ml) and water (2x50ml). After which the solution is dried over magnesium sulfate, filtered and evaporated. The product is purified using column chromatography on a gradient system

from ethyl acetate 40%: hexane to ethyl acetate. This yields approximately 6.7g (77.8%) of the product as a colorless oil.


5 Linker arm synthesis with other functionalities

The linker arms of the present invention may be synthesized with other functionalities, including a chloride and an amine functionality. The synthesis of these compounds is outlined in chart 11, below. The amino functionality may also be attached to drugs or biologically active molecules such as cholesterol, proteins and antibodies, via an amide linker.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100



10/22/2019 10:24:30 AM



5 Chart 11.

- (i) sodium, ethanol, para-methoxy- α -toluene thiol, reflux 24 hours;
(ii) thionyl chloride, pyridine; (iii) potassium phthalimide; (iv) hydrazine

8-(4-Methoxybenzylthio)-3,6-dioxaoctyl chloride (31)

8-(4-Methoxybenzylthio)-3,6-dioxaoctanol (1.72g, 6 mmols) is
5 dissolved in dry dichloromethane (30ml) and dry pyridine (0.97ml, 12
mmols) is added. The solution is stirred for 5 minutes then thionyl
chloride (0.5ml) is added. The mixture is heated at reflux overnight. Then
it is poured into hydrochloric acid (2M, 25ml) and the organic layer is
separated. The aqueous solution is extracted with dichloromethane (2x25
10 ml) and the combined organic extracts are washed with water (10ml).
After drying over magnesium sulfate the solution is filtered and
evaporated. The product is purified using silica gel chromatography
eluted with a gradient system from petroleum ether 60%: diethyl ether to
petroleum ether 40%: diethyl ether. This yields approximately 0.39g
15 (57%) of the product as a colorless oil.

8-(4-Methoxybenzylthio)-1-(N-phthalimido)-3,6-dioxaoctane (32)

8-(4-Methoxybenzylthio)-3,6-dioxaoctyl chloride (0.53g, 1.7 mmols)
20 is dissolved in dimethyl formamide and potassium phthalimide (0.32g, 2
mmols) is added. The mixture is heated at 100°C for 18 hours and then
cooled to room temperature. It is poured into water (100ml) and

extracted with diethyl ether (3x100 ml), after drying over magnesium sulfate it is filtered and evaporated. The product is purified using silica gel chromatography eluted with a gradient system from petroleum ether 60%: diethyl ether to petroleum ether 40%: diethyl ether. This gave 0.39g
5 (57%) of the product as a colorless oil.

8-(4-Methoxybenzylthio)-3,6-dioxaoctylamine (33)

8-(4-Methoxybenzylthio)-1-(N-phthalimido)-3,6-dioxaoctane (0.39g, 0.96 mmols) is dissolved in absolute ethanol and hydrazine hydrate (1ml)
10 is added. The mixture is heated at reflux for 1 hour and the solvent is removed under reduced pressure.

Water (10ml) and sodium hydroxide solution (1M, 10ml) are added to the resulting tar and the product is extracted with diethyl ether (3x50ml).


The ethereal solution is dried over magnesium sulfate filtered and

15 evaporated to yield approximately 0.25g (92%) of the product as an oil.

5

Attachment of biologically active compounds to the linker arm

A biologically active organic compound may be attached to the linker arm as follows:



10

Where X is Cl, Br, I, OTs, OMs, OTf, NH₂, SH, OH, C=O, COCl, CO₂H, etc.

The biologically active molecule is attached to the linker arm via a functional group or a methylene group. R may be O, NH, S, CH₂, etc. PG is a protecting group and may be para-methoxy benzyl, benzyl, a thioamide, a thio ether, etc.

5 Attaching linker arms to nanocrystal core shells

This example discloses a method of attaching linker arms of the present invention to nanocrystal core shells. An example of the methodology used is outlined below:

10 9 mg of trioctylphosphine oxide coated core shells are weighed out and suspended in pyridine (2ml). The concentration and thus the number of moles of nanocrystals may be determined before hand using UV-vis spectroscopy. This suspension is stirred at 60°C for 24 hours, N-(4-(3-[4-(2-
15 Benhydrixyethyl)piperazine-1-yl]propyl)phenyl-2-[2-(2-mercaptoethoxy)ethoxy] acetamide (25), (100mg) is dissolved in dichloromethane (100ml) and 2.7ml of this solution is added to the solution of nanocrystals. This gives approximately 100 ligands per core shell. The solution is stirred at 60°C under argon for 2 hours. Upon cooling to room temperature the solution is added to hexanes.
20 Ligand coated core shells crystallise out of solution and are collected by filtration.

The water solubility of the ligand functionalised core shells may be increased if necessary by using a modification of the method of Fred Mikulec (private communication). Mercaptoacetic acid (1ml) and dimethyl formamide (1ml) are added to the ligand coated core shells and stirred at room temperature
5 under argon for 2 hours. After cooling to room temperature the solution is diluted with dimethyl formamide (100ml) and potassium tertiary butoxide (1.61g) is added. The resulting solid is collected by centrifugation and is washed with tetrahydrofuran (4 x 100ml) and methanol (7 x 100ml). The product is collected by centrifugation to yield 45 mg of
10 1-[2-bisphenylmethoxy]ethyl]-4-(3-(4-(3,6-dioxa-8-thiol)octanamidophenyl)propyl piperazine (25) coated nanocrystals. After drying the precipitate under reduced pressure for 4 days at room temperature the ligand coated cores can be dissolved in a minimum quantity of buffer in a pH range of 6 to 8.

15 This invention thus being described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the present invention, and all such modifications as would be obvious to one of ordinary skill in the art are intended to be included within the scope of the following claims.

20 All cited patents and publications referred to in this application are herein expressly incorporated by reference.